Teleflex (NYSE:TFX) Given Hold Rating at Needham & Company LLC

Teleflex (NYSE:TFX)‘s stock had its “hold” rating reiterated by investment analysts at Needham & Company LLC in a report issued on Friday, Benzinga reports.

TFX has been the topic of a number of other reports. Stephens upped their target price on shares of Teleflex from $275.00 to $290.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Royal Bank of Canada lifted their target price on Teleflex from $260.00 to $275.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Finally, Truist Financial lifted their price objective on Teleflex from $247.00 to $255.00 and gave the stock a “hold” rating in a research report on Monday, October 14th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Teleflex presently has a consensus rating of “Moderate Buy” and a consensus price target of $262.75.

Teleflex Stock Up 5.0 %

NYSE TFX opened at $211.21 on Friday. The stock’s 50 day simple moving average is $239.55 and its 200 day simple moving average is $224.02. Teleflex has a one year low of $190.49 and a one year high of $257.85. The firm has a market cap of $9.95 billion, a PE ratio of 41.99, a price-to-earnings-growth ratio of 1.82 and a beta of 1.18. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.44.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, October 31st. The medical technology company reported $3.49 earnings per share for the quarter, beating analysts’ consensus estimates of $3.38 by $0.11. The company had revenue of $764.40 million during the quarter, compared to analyst estimates of $768.68 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The firm’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same period last year, the company posted $3.64 earnings per share. As a group, sell-side analysts forecast that Teleflex will post 13.97 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Stuart A. Randle sold 2,674 shares of Teleflex stock in a transaction on Friday, August 16th. The shares were sold at an average price of $238.93, for a total transaction of $638,898.82. Following the transaction, the director now directly owns 5,496 shares of the company’s stock, valued at $1,313,159.28. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.43% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Teleflex

Hedge funds have recently modified their holdings of the business. Cromwell Holdings LLC raised its holdings in Teleflex by 59.0% during the 3rd quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company’s stock worth $33,000 after buying an additional 49 shares during the period. GAMMA Investing LLC boosted its position in shares of Teleflex by 131.1% during the third quarter. GAMMA Investing LLC now owns 171 shares of the medical technology company’s stock worth $42,000 after buying an additional 97 shares during the period. Canada Pension Plan Investment Board bought a new position in shares of Teleflex during the second quarter worth about $42,000. Versant Capital Management Inc raised its holdings in shares of Teleflex by 20,700.0% in the second quarter. Versant Capital Management Inc now owns 208 shares of the medical technology company’s stock valued at $44,000 after purchasing an additional 207 shares during the last quarter. Finally, Blue Trust Inc. increased its stake in Teleflex by 78.2% in the 2nd quarter. Blue Trust Inc. now owns 212 shares of the medical technology company’s stock valued at $48,000 after buying an additional 93 shares during the last quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.